---
layout: page
title: Therapeutic neutralization of the Interleukin-17 pathway in ALS 
description:
# img: assets/img/12.jpg
importance: 1
category: active
related_publications: false
---

Systemic and neural inflammation that occurs in ALS patients is typified by elevation of the inflammatory cytokine IL-17A in ALS patient plasma and cerebral spinal fluid. Th17 T cells, the major cell type that produce IL-17A, are elevated in ALS patient blood and this Th17 elevation correlates with a more rapid ALS disease progression. IL-17A induces neurotoxic neutrophils that are elevated in ALS patient blood and cerebral spinal fluid and higher neutrophil levels correlate with poorer ALS patient survival. Mice that model the C9ORF72 repeat expansion â€“ the most common genetic cause of ALS - develop elevated levels of IL-17A in plasma, have elevated Th17 cells and neutrophils in the blood and experience neural inflammation. We demonstrated that neutralization of IL-17A with blocking antibodies administered outside the central nervous system of C9orf72 mutant mice reduced neutrophils in blood, reduced neural inflammation of the spinal cord, and improved motor function. We seek to evaluate whether therapeutic neutralization of IL-17A in ALS patients to halt systemic and neural inflammation, slow motor decline, extend lifespan and improve patient quality of life using FDA approved humanized IL-17A neutralizing antibodies that are routinely prescribed in the clinic to treat psoriasis. 


